Podcasts about semaglutide

En este episodio hablo con el Dr. Javier Muñoz sobre la hormona GLP-1, más conocida como Ozempic, Semaglutide o Mounjaro. Descubrí qué hay detrás del boom mundial: sus beneficios reales, cómo actúa en el cuerpo y lo que nadie te cuenta.Disclaimer: Este episodio es educativo e informativo. No sustituye la consulta médica.Dale play y compartilo con alguien que también quiera entender de qué se trata todo este boom del GLP-1.Recordá: cuidar tu cuerpo también es honrar el regalo de la vida.

Send us a textWhat if everything you thought you knew about weight loss was wrong? In this powerful conversation, Joey Pinz sits down with Dr. David Plourdé—scientist, author of Solving the Weight Loss Puzzle, and founder of The Plourde Method—to uncover the real science behind lasting fat loss.Dr. Plourdé shares insights from 34 years in the lab, where he studied fat cells, food addiction, and the hidden forces sabotaging our health. From uncovering insidious carbs in everyday foods to exposing the dark side of weight-loss drugs like Ozempic, his revelations will make you rethink nutrition, exercise, and the role of psychology in transformation.✨ Top 3 Highlights:

Sick of trying fad diets that just don't seem to work for you? Find out how to simplify your approach and succeed by learning and applying the principles of weight management.  How to make calories work for you Which proteins are better than others and when to eat protein Preserving lean muscle while losing body fat "Dirty" vs "Clean" diets Including desert and candy during a weight loss journey   APEX RX https://apexrx.net   Jesse Frank https://www.lvrgfit.com jesse.dfrank@gmail.com   Charlie Seltzer https://drseltzerlifestylemedicine.com info@drseltzerweightloss.com

AI accelerates drug discovery while steroids turn teens into aggressive strangers. Dr. Michael Israetel explores our pharmaceutical crossroads here!Full show notes and resources can be found here: jordanharbinger.com/1209What We Discuss with Michael Israetel:GLP-1 drugs like Tirzepatide offer massive health benefits beyond weight loss — reducing inflammation, improving brain health, and decreasing addiction behaviors, even for people already in good shape.Steroids don't just amplify personality — they specifically amplify masculine traits like aggression and reduce empathy. Starting young can permanently rewire your brain's emotional and social processing.AI is about to revolutionize medicine by testing millions of drug candidates virtually, creating treatments 10x more effective with 10x fewer side effects. We're entering the pharmaceutical iPhone moment.The "only take drugs when sick" mindset worked in the 20th century, but is becoming dangerously outdated — like refusing elevators because you prefer human operators.When your diet plateaus, take a week-long break eating at maintenance. Your stress hormones will drop, body water will flush out, and you'll often look leaner than before.And much more...And if you're still game to support us, please leave a review here — even one sentence helps! Sign up for Six-Minute Networking — our free networking and relationship development mini course — at jordanharbinger.com/course!Subscribe to our once-a-week Wee Bit Wiser newsletter today and start filling your Wednesdays with wisdom!Do you even Reddit, bro? Join us at r/JordanHarbinger!This Episode Is Brought To You By Our Fine Sponsors:Saily: 15% off: saily.com/jordanharbinger, code JORDANHARBINGERDripDrop: 20% off: DripDrop.com, code JORDANLinkedIn Jobs: Post your job for free: linkedin.com/jordanQuince: Free shipping & 365-day returns: quince.com/jordanBetterHelp: 10% off first month: betterhelp.com/jordanSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode, Shana Hussin, RDN, shares the replay of her recent webinar on GLP-1 — the hormone behind today's most popular weight loss drugs like Ozempic, Wegovy, and Mounjaro. You'll learn: ✔️ What GLP-1 is and how it works in the body ✔️ Natural ways to increase GLP-1 for fewer cravings, better blood sugar, and fat loss ✔️ Lifestyle habits that decrease GLP-1 and fuel insulin resistance ✔️ The truth about GLP-1 medications: cost, side effects, and sustainability ✔️ How to safely transition off GLP-1 drugs by improving natural GLP-1 and gut health ✔️ The research behind Unimate Yerba Mate and Balance Fiber Matrix — and how they support GLP-1 signaling in the Feel Great System ✨ If you've ever wondered whether you really need expensive GLP-1 medications, or if there's a more sustainable, root-cause solution, this episode is for you. Resources & Links:

Special edition of the JAMA Editor's Summary featuring the JAMA Network articles published at the 2025 European Society of Cardiology Congress. Hosted by JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, with JAMA Executive Editor Gregory Curfman, MD, JAMA Senior Editor Philip Greenland, MD, and JAMA Cardiology Editor Robert O. Bonow, MD, MS. Related Content: Remote Screening for Asymptomatic Atrial Fibrillation Long-Term Anticoagulation Discontinuation After Catheter Ablation for Atrial Fibrillation Systolic Blood Pressure and Microaxial Flow Pump–Associated Survival in Infarct-Related Cardiogenic Shock Helicobacter pylori Screening After Acute Myocardial Infarction Physiology-Guided Complete Revascularization in Older Patients With Myocardial Infarction Fractional Flow Reserve–Guided Complete vs Culprit-Only Revascularization in Non–ST-Elevation Myocardial Infarction and Multivessel Disease Transcatheter or Surgical Treatment of Patients With Aortic Stenosis at Low to Intermediate Risk Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction Bivalent RSV Prefusion F Protein–Based Vaccine for Preventing Cardiovascular Hospitalizations in Older Adults High-Dose vs Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults Risk of Myocarditis or Pericarditis With High-Dose vs Standard-Dose Influenza Vaccine Clonal Hematopoiesis and Risk of New-Onset Myocarditis and Pericarditis Participation of Women in Cardiovascular Trials From 2017 to 2023 Prevalence, Determinants, and Time Trends of Cardiovascular Health in the WHO African Region

Semaglutide drug Wegovy has been available in New Zealand for a couple of months now, and more Kiwis are learning about the effects. The drug has transformed our ability to manage obesity and type 2 diabetes, and has shown potential for a wide range of conditions such as Alzheimer's, addiction and depression. General Practice NZ chair Dr Bryan Betty joined the Afternoons team to discuss further - and highlight some potential drawbacks. LISTEN ABOVESee omnystudio.com/listener for privacy information.

Open Bodybuilding Olympian, 3x IFBB Pro Champion, pro podcaster in the IFBBAMA and can be often seen on Bodybuilding & Bollocks on the Real Bodybuilding Podcast.Watch it: https://youtu.be/gPfRK3HoAAYThe Bodybuilding-friendly HRT Clinic - Get professional medical guidance on peptides AND optimizing your health as a man or bodybuilder: [ Pharma Test, IGF1, Tesamorelin, Glutathione, BPC, Semaglutide, Var troche, etc]http://www.transcendcompany.com/nylenaygaRP Hypertrophy Training App: rpstrength.com/nylePlease share this episode if you liked it. To support the podcast, the best cost-free way is to subscribe and please rate the podcast 5* wherever you find your podcasts. Thanks for watching.To be part of any Q&A, follow trensparentpodcast or nylenayga on instagram and watch for Q&A prompts on the story  https://www.instagram.com/trensparentpodcast/Huge Supplements (Protein, Pre, Defend Cycle Support, Utilize GDA, Vital, Astragalus, Citrus Bergamot): https://www.hugesupplements.com/discount/NYLESupport code 'NYLE' 10% off - proceeds go towards upgrading content productionYoungLA Clothes: https://www.youngla.com/discount/nyleCode ‘NYLE' to support the podcastLet's chat about the Podcast:Instagram: https://www.instagram.com/trensparentpodcast/TikTok: https://www.tiktok.com/@transparentpodcastPersonalized Bodybuilding Program:  https://www.nylenaygafitness.comTimestamps:00:00 Intro to James Hollingshead04:40 Early Bodybuilding Journey and Influences09:18 Deep Dive into Nutrition and Longevity19:16 Steroid Use and Its Impact on Career26:14 Mindset and Overcoming Hardships38:00 Health Monitoring and Genetics46:20 Optimizing Training Splits57:46 Balancing Bodybuilding and Mental Health01:07:25 Dealing with Loss and Finding Purpose01:18:56 Favorite Prep Memories01:26:04 Best Peaking Show Memories01:33:27 Truth About Dosages01:45:36 Rep Ranges for Hypertrophy01:51:35 Offseason Strategy: Mass vs Conditioning01:55:24 Fertility While on Cycle01:57:14 Favorite Compounds02:00:02 Appreciating the Whole Physique02:04:23 Views on Lifting Styles02:07:51 Balancing Fatherhood and Bodybuilding02:14:45 Therapy and Travel Insights02:17:56 Final Message to the World

Olivia emailed us sharing her personal journey with Semaglutide, a GLP one receptor agonist, and how it helped her manage binge eating disorder. Olivia's experience was so compelling and we believe it sheds light on the silence around GLP one drugs and their potential benefits beyond weight loss. Join Georgie as she discusses the implications, potential benefits, and risks of using these medications for binge eating disorder. She also delves into the future of research and the pharmaceutical industry in this space. This episode is a must-listen for anyone curious about the real-life impacts of GLP one drugs on binge eating disorder.For more information, check out these references below:https://www.sciencedirect.com/science/article/pii/S2667368123000268https://www.sciencedirect.com/science/article/abs/pii/S0924977X24000646https://doi.org/10.1016/j.dsx.2020.03.00900:00 Introduction to Olivia's Story01:33 Olivia's Background and Binge Eating Journey05:03 Starting Semaglutide: Initial Experiences09:03 Impact on Mental Health and Relationships18:38 Public Perception and Stigma25:16 Opening Up About Personal Struggles27:42 The Impact of Medication on Binge Eating30:55 Alcohol and Medication Effects33:07 Cognitive Behavioral Therapy and Mental Space38:21 Redefining Life Without Food Noise40:44 Final Thoughts and Recommendations46:26 Research and Future Directions for GLP-1 DrugsConnect with Georgie and the Confident Eaters Coaches: WebsiteFacebookInstagramHave you ever thought, "I know what to do, I just need to consistently do it"? Who hasn't? Sometimes we need accountability. Sometimes we need specific strategies, new tools, or a bit of help. If you are want help to become a confident, sensible eater with 1:1 personalized attention, sign up at ConfidentEaters.com.

Markus Hunter IFBB Pro:  ⁨@Markusfit⁩  The Bodybuilding-friendly HRT Clinic - Get professional medical guidance on peptides AND optimizing your health as a man or bodybuilder: [ Pharma Test, IGF1, Tesamorelin, Glutathione, BPC, Semaglutide, Var troche, etc]http://www.transcendcompany.com/nylenaygaRP Hypertrophy Training App: rpstrength.com/nylePlease share this episode if you liked it. To support the podcast, the best cost-free way is to subscribe and please rate the podcast 5* wherever you find your podcasts. Thanks for watching.To be part of any Q&A, follow trensparentpodcast or nylenayga on instagram and watch for Q&A prompts on the story  https://www.instagram.com/trensparentpodcast/Huge Supplements (Protein, Pre, Defend Cycle Support, Utilize GDA, Vital, Astragalus, Citrus Bergamot): https://www.hugesupplements.com/discount/NYLESupport code 'NYLE' 10% off - proceeds go towards upgrading content productionYoungLA Clothes: https://www.youngla.com/discount/nyleCode ‘NYLE' to support the podcastLet's chat about the Podcast:Instagram: https://www.instagram.com/trensparentpodcast/TikTok: https://www.tiktok.com/@transparentpodcastPersonalized Bodybuilding Program:  https://www.nylenaygafitness.comTimestamps:0:00 - Intro5:43 - Social Media Perceptions and TikTok Labels10:00 - Content Creation Struggles and Polarization17:15 - Reasons for Mindset Change20:00 - Constructive Criticism and Impact Stories26:43 - Insane Tren Doses and Variations30:00 - Gear, Genetics, and Growth36:38 - Learning Your Body and Coaching45:56 - Sleep Aids and Health Risks50:00 - Crazy Cycle Stories58:19 - Back Training Revelations59:47 - Men's Physique vs. Open Bodybuilding1:10:00 - Chasing the Pro Card Reality1:20:00 - Pro Card Struggles and Triumphs1:28:20 - Importance of Sex in Relationships01:29:56 - Best Prep Look Without Diuretics1:40:22 - Cycle variations01:49:12 - Biohacking for Optimal Performance01:59:40 - Evolving Training Strategies2:10:00 - Next Pod Plans02:12:38 -Best way to use superdrol02:18:57 - Growth Hormone02:30:46 - Gear Guidance for Newbies02:36:05 - Gut Health2:50:00 - Long Prep Secrets02:57:12 - the final message02:59:26 - Being Self/ Family Centered as Men

[00:00] Intro banter and chaotic energy kicks off the show[02:30] Storytime: Jack breaks a door, hilarity ensues[12:00] Commentary on Ozempic, semaglutide, and weight-loss trends[22:45] Is Nelly Furtado Puerto Rican? Plus pop culture weight changes[30:00] The invention of the "Ozempic Olympics" (listener suggestions welcome)[35:15] Gen X slang deep-dive (what phrases will never die?)[43:00] The Rock and celebs adapting to aging—humorously dissected[49:30] The "America Quiz" — challenging each other's patriot knowledge[01:00:00] Wrap-up, random laughs, and Fred's memorable shout-out #blcpodcast #podcastingforthepeople #funny #podcast #greenvillesc #scpodcast #yeahthatgreenville Listen at: https://americasfavoritepodcast.com Tweet the Show: https://twitter.com/blcworld Follow us on Facebook: https://www.facebook.com/blcpodcast/ Check us out on Instagram: https://www.instagram.com/blcpodcast/ Buy Fred and Allan Beer: https://www.patreon.com/blcworld

Diabetes Core Update is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association's four science and medical journals – Diabetes, Diabetes Care, Clinical Diabetes, and Diabetes Spectrum. Each episode is approximately 25 minutes long and presents 5-6 recently published articles from ADA journals. Intended for practicing physicians and health care professionals, Diabetes Core Update   discusses how the latest research and information published in journals of the American Diabetes Association are relevant to clinical practice and can be applied in a treatment setting. Welcome to diabetes core update where every month we go over the most important articles to come out in the field of diabetes. Articles that are important for practicing clinicians to understand to stay up with the rapid changes in the field.  This issue will review:   1.     Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity  - NEJM   2.     Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3)– Lancet Diabetes Endocrinology    3.     Nutritional priorities to support GLP-1 therapy for Obesity – A Joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society - American Journal of Clinical Nutrition 4.     Gradual Titration of Semaglutide Results in Better Treatment Adherence and Fewer Adverse Events – Diab Care 5.     Tirzepatide as Compared with Semaglutide for the Treatment of Obesity – NEJM For more information about each of ADA's science and medical journals, please visit Diabetesjournals.org. Hosts: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health

Episode Summary: Summer may have been fun, but if your energy, weight, or motivation feel off, you're not alone. This solo episode is your permission slip to stop the extremes and start fresh—with a metabolism reset grounded in balance, not burnout. Shana walks you through why so many women feel worse after summer, and what to do now to feel amazing again—without restrictive dieting or relying on medications like Ozempic, metformin, or statins. If you're feeling puffy, tired, or stuck, this episode will show you how to gently reset your metabolism, support your hormones, and finally feel great again. 

Send us a textKey Opinion Leaders Manal Abdelmalek, Naim Alkhouri, Scott Isaacs and Zobair Younossi join Roger Green to discuss the FDA's approval of semaglutide for patients with non-cirrhotic MASH. This conversation centers on the roles that new technologies and an expanded APP population will play in MASLD and MASH management in the US, and concludes by exploring how care might look different 12 months from now, and then in subsequent years. As panelists identify some of the changes they foresee if we are to manage the tsunami of undiagnosed MASLD patients, many comments touch on themes discussed earlier in this episode. A couple are unique. Zobair and Scott discuss the increased role that artificial intelligence and big data analytics will play in identifying high-risk patients and improving clinical pathways. Additionally, Zobair notes that we must remember that the vast majority of MASLD patients will never develop MASH. Manal foresees a more sophisticated approach to selecting pharmacotherapies as prescribers have a broader set of options, each with its own benefits and drawbacks. Scott anticipates a "paradigm shift" in which endocrinologists view MASH similarly to how they view retinopathy, neuropathy and retinopathy. Naim suggests that one year will not look tremendously different from today, but that five years from now will be an entirely different picture, which he describes in some detail. 

The Bodybuilding-friendly HRT Clinic - Get professional medical guidance on peptides AND optimizing your health as a man or bodybuilder: [ Pharma Test, IGF1, Tesamorelin, Glutathione, BPC, Semaglutide, Var troche, etc]http://www.transcendcompany.com/nylenaygaRP Hypertrophy Training App: rpstrength.com/nylePlease share this episode if you liked it. To support the podcast, the best cost-free way is to subscribe and please rate the podcast 5* wherever you find your podcasts. Thanks for watching.To be part of any Q&A, follow trensparentpodcast or nylenayga on instagram and watch for Q&A prompts on the story  https://www.instagram.com/trensparentpodcast/Huge Supplements (Protein, Pre, Defend Cycle Support, Utilize GDA, Vital, Astragalus, Citrus Bergamot): https://www.hugesupplements.com/discount/NYLESupport code 'NYLE' 10% off - proceeds go towards upgrading content productionYoungLA Clothes: https://www.youngla.com/discount/nyleCode ‘NYLE' to support the podcastLet's chat about the Podcast:Instagram: https://www.instagram.com/trensparentpodcast/TikTok: https://www.tiktok.com/@transparentpodcastPersonalized Bodybuilding Program:  https://www.nylenaygafitness.comTimestamps:00:00:00 Intro00:02:08 Coaching Men vs Women & Hormone Challenges00:06:55 Discovering Bodybuilding & Early Training Mistakes00:11:26 First Competition & Prep Lessons00:15:39 Diuretics vs Natural Peaking00:21:17 Athlete Examples & Conditioning Standards00:25:37 Precision in Bodybuilding & Coaching Start00:31:50 Success with Physique Athlete & Olympia Journey00:36:00 Meeting & Working with Terrence Ruffin00:44:13 Fullness, Dryness & Peaking Challenges00:49:32 Coach–Athlete Learning Curve & Comparisons00:55:49 Classic Physique: Shape vs Conditioning01:02:42 Defining a Good Coach & Athlete Safety01:08:48 Health Supplements & Blood Work Frequency01:15:10 Downsizing for Classic Physique & Compound Choices01:22:12 Individual Reactions & Instagram Misinformation01:26:56 Food Intolerances & Insulin Sensitivity Tips01:33:55 Blood Pressure & Root Problem Fixes01:34:54 Off-Season Training Focus & Nutrition01:39:48 Intensifiers01:44:36 Coaching Anxiety & Life Perspective Shifts01:51:29 Olympia Wins & Chasing Coaching Legends01:55:25 Tips for Young Self & Helping Athletes02:05:05 Tren in Men's Physique & Side Effect Management02:17:53 Hyacine's Proudest Moment02:20:59 Superior Genetics?02:22:34 Clen Use & Side Effects02:33:52 Dubai Bodybuilding Scene & Gyms02:37:34 Dubai Lifestyle & Safety02:42:12 Advice for New Coaches & Mentorship02:46:50 Final Message & Podcast Wrap-Up

Special edition of the JAMA Editor's Summary featuring the JAMA Network articles published at the 2025 European Society of Cardiology Congress. Hosted by JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, with JAMA Executive Editor Gregory Curfman, MD, JAMA Senior Editor Philip Greenland, MD, and JAMA Cardiology Editor Robert O. Bonow, MD, MS. Related Content: Remote Screening for Asymptomatic Atrial Fibrillation Long-Term Anticoagulation Discontinuation After Catheter Ablation for Atrial Fibrillation Systolic Blood Pressure and Microaxial Flow Pump–Associated Survival in Infarct-Related Cardiogenic Shock Helicobacter pylori Screening After Acute Myocardial Infarction Physiology-Guided Complete Revascularization in Older Patients With Myocardial Infarction Fractional Flow Reserve–Guided Complete vs Culprit-Only Revascularization in Non–ST-Elevation Myocardial Infarction and Multivessel Disease Transcatheter or Surgical Treatment of Patients With Aortic Stenosis at Low to Intermediate Risk Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction Bivalent RSV Prefusion F Protein–Based Vaccine for Preventing Cardiovascular Hospitalizations in Older Adults High-Dose vs Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults Risk of Myocarditis or Pericarditis With High-Dose vs Standard-Dose Influenza Vaccine Clonal Hematopoiesis and Risk of New-Onset Myocarditis and Pericarditis Participation of Women in Cardiovascular Trials From 2017 to 2023 Prevalence, Determinants, and Time Trends of Cardiovascular Health in the WHO African Region

Send us a textKey Opinion Leaders Manal Abdelmalek, Naim Alkhouri, Scott Isaacs and Zobair Younossi join Roger Green to discuss  FDA's approval of semaglutide for patients with non-cirrhotic MASH. This conversation focuses on benefits for patients and ways that having two drugs with different modes of action will change pharmacotherapy choices.This conversation starts with the group describing the sense of "enthusiasm" and "fulfillment" hepatology drug developers feel to see two drugs approved in the US and many other major changes to come (more drug approvals, FDA acceptance of a path to approval that is not based on liver biopsy). One interesting takeaway is that while the approval of semaglutide will likely change the number of patients treated with MASH pharmacotherapy, the greater impact of this approval will be on public awareness of MASH and the accompanying demand for treatment. In terms of actual drug use, the first major change will come among patients living with obesity but not Type 2 diabetes. Most of these patients previously saw their semaglutide prescriptions rejected for payment by health insurers. However, many of these patients will be living with MASH, and they are likely to see their prescriptions approved. Instead, the largest impact may involve increased education and awareness. Scott pointed out that endocrinologists, who frequently prescribe incretin agonists, will have reason to learn how to diagnose and manage MASH in patients they already treat. Zobair noted that an array of companies, starting with pharmaceutical manufacturers and scanning companies, will dramatically increase investments in prescriber and patient education. Another important benefit may come in terms of coverage. Scott points out that most patients living with obesity but not diabetes are unlikely to have their semaglutide prescriptions covered by commercial insurers. Those living with non-cirrhotic MASH are likely to have semaglutide covered. A separate but related point: Naim reports that ~30% of the MASH patients he sees are taking an incretin agonist at the time of initial visit.

Send us a textKey Opinion Leaders Manal Abdelmalek, Naim Alkhouri, Scott Isaacs and Zobair Younossi join Roger Green to discuss the FDA's approval of semaglutide for patients with non-cirrhotic MASH. This conversation focuses on how the US healthcare system must adapt to handle the growing number of MASH and MASLD patients who might seek treatment, given likely increases in publicity and education.The conversation starts with a focus on the implications of semaglutide approval for hepatologists. Naim states that many hepatologists are currently uncomfortable managing patients on GLP-1 agonists. This will need to change. Manal points out that providers must check for cirrhosis when testing for MASH and understand how to respond accordingly. An increase in the number of providers having access to in-office scanning devices will facilitate this process.Zobair shifts to a larger point:  even if all related specialists integrate MASH into their practices, the actual patient care demand will require alternative pathways in which the responsibility for patient care will rest with specialist APPs. The number of APPs necessary to handle this load and trained to do so does not currently exist in the US. Increased APP training must, and will, become an area for increased investment and focus.After Naim Alkhouri describes some of the differences between resmetirom and semaglutide in terms of practical treatment decisions, the discussion focuses on why MASLD and MASH will create unique challenges for hepatology practices. Manal views the issue as a matter of time; practices cannot absorb large numbers of new, non-urgent patients. Naim suggests that the real issue is the business question: specialists today do not profit simply from treating patients. Zobair agrees with Naim and notes that the challenge is not unique to hepatology. He expresses the hope that AI and efficient database management will make it easier to target, screen, diagnose and treat patients...given sufficient providers (mostly APPs) to treat them. 

Send us a text00:00:00 - Surf's Up, Season 6, Episode 12This week's episode is a special three-part roundtable on the implications of the FDA's recent approval of semaglutide. Naim Alkhouri, Manal Abdelmalek, Scott Isaacs and Zobair Younossi join Roger Green in a discussion that focuses less on specifics of pharmacotherapy and more on how having two drugs available will change MASH management in the US.00:08:45 - Part I: How Will The Semaglutide Approval Affect Patient Treatment and Pharmacotherapy?The group starts by describing the sense of "enthusiasm" and "fulfillment" hepatology drug developers feel to see two drugs approved in the US and many other major changes to come (more drug approvals, FDA acceptance of a path to approval that is not based on liver biopsy). One interesting takeaway is that while the approval of semaglutide will likely change the number of patients treated with MASH pharmacotherapy, the greater impact of this approval will be on public awareness of MASH and the accompanying demand for treatment. In terms of actual drug use, the first major change will come among patients living with obesity but not Type 2 diabetes. Most of these patients previously saw their semaglutide prescriptions rejected for payment by health insurers. However, many of these patients will be living with MASH, and they are likely to see their prescriptions approved. Instead, the largest impact may involve increased education and awareness. Scott pointed out that endocrinologists, who frequently prescribe incretin agonists, will have reason to learn how to diagnose and manage MASH in patients they already treat. Zobair noted that an array of companies, starting with pharmaceutical manufacturers and scanning companies, will dramatically increase investments in prescriber and patient education.00:25:30 - Part II: How the Structure of Medical Practice Is Likely To ChangeNaim states that many hepatologists are currently uncomfortable managing patients on GLP-1 agonists. This will need to change. Manal points out that providers must check for cirrhosis when testing for MASH and understand how to respond accordingly. An increase in the number of providers having access to in-office scanning devices will facilitate this process. Zobair states that even if all related specialists integrate MASH into their practices, the actual patient care demand will require alternative pathways in which the responsibility for patient care will rest with specialist APPs. After Naim Alkhouri describes some of the differences between resmetirom and semaglutide in terms of practical treatment decisions, the discussion focuses on why MASLD and MASH will create unique challenges for hepatology practices. Manal views the issue as a matter of time; practices cannot absorb large numbers of new, non-urgent patients. Naim suggests that the real issue is the business question: specialists today do not profit simply from treating patients. Zobair agrees with Naim and notes that the challenge is not unique to hepatology. He expresses the hope that AI and efficient database management will make it easier to target patients, screen, diagnose and treat them. 00:44:17 - Part III: What Happens Next?In this final section, panelists identify some of the changes they foresee if we are to manage the tsunami of undiagnosed MASLD patients. Many of the comments touch on themes discussed earlier in this episode, but a couple are unique. Zobair states we must remember that the vast majority of MASLD patients will never develop MASH. Manal foresees a more sophisticated approach to selecting pharmacotherapies as prescribers have a broader set of options, each with its own benefits and drawbacks. Scotts anticipates a "paradigm shift" in which providers come to view MASH similarly to how they view diabetic comorbidities. 

In this episode of the RWS Clinician's Corner, Margaret Floyd Barry sits down with Dr. Tyna Moore—renowned naturopathic physician, chiropractor, and international speaker with almost 30 years of experience in holistic and regenerative medicine. Dr. Tyna is known for her bold approach to metabolic health, especially her unique use of GLP-1 agonists like semaglutide, not just for weight loss but as powerful tools for longevity, healing, and resilience. Dr. Tyna pulls back the curtain on the true clinical potential of these peptides, busting myths and exploring the nuance lost in today's clickbait headlines.   In this interview, we discuss:   The science behind GLP-1s and GLP-1 Agonists (including mechanism of action and effects) Microdosing/personalized dosing of GLP-1s, including clinical uses beyond weight loss The concept of “cycling” versus lifelong usage (compared to hormone therapy) Potential side effects and dosing management (including contraindications and safety) Compounded GLP-1s: access, regulations, and practicalities Industry resistance, misinformation, and social dynamics Using GLP-1s during gut healing protocols and the limits of natural alternatives The Clinician's Corner is brought to you by Restorative Wellness Solutions.  Follow us: https://www.instagram.com/restorativewellnesssolutions/    Connect with Dr. Tyna Moore: Website: http://www.drtyna.comInstagram: https://www.instagram.com/drtyna/ YouTube: https://www.youtube.com/@drtyna   Click here for Dr. Tyna's Free 4-part video Series, GLP-1 Uncovered. This video series concludes with an offer for her course, GLP-1s Done Right University. Enter coupon code MARGARET to receive a special discount: https://www.drtyna.com/ozempicuncovered   Or, to go directly to the course, GLP-1s Done Right University, click here and enter the same coupon code (MARGARET) to get started.  Timestamps: 00:00 Regenerative Medicine and Hormone Therapy  05:57 Functional Medicine Truth vs. Propaganda  14:17 Regenerative Therapy Requires Low Inflammation  16:08 Widespread Cardiometabolic Health Crisis  22:16 "Managing Health Challenges with Medication"  30:29 "Low-Dose Approach for Diabetes Management"  36:16 "Empowering Patients Through Education"  38:58 Custom Medication Dosing Benefits  44:43 503B Compounding Pharmacies Shutdown  52:51 Understanding Peptides in Modern Healthcare  57:15 Biliary Concerns in GLP-1 Use  59:14 Liver Health and Supplement Advice  01:06:57 Optimizing Gut Microbiome Strategies  01:10:17 "GLP-1 for Health Improvement" 01:15:29 "Rediscovering Physical Fitness" Speaker bio:    With nearly thirty years immersed in the medical field, Dr. Tyna Moore is an expert in holistic regenerative medicine and resilient metabolic health. She is licensed as a Naturopathic Physician and a Chiropractor, drawing on knowledge from both traditional and alternative fields of science and medicine to provide a comprehensive perspective to individuals striving to enhance their health and wellbeing. Dr. Tyna holds degrees from the National College of Natural Medicine, an esteemed naturopathic medical school, and the University of Western States Chiropractic College. Her work is not just about treating symptoms, it's about understanding and healing root causes to build a robust foundation for long term wellbeing. She is well known for her fierce and open-minded exploration of the peptide, Semaglutide/Ozempic, as a longevity tool for healing. Dr. Tyna champions medical autonomy and individual accountability, and she is on a mission to help as many people as possible experience the freedom and joy that health brings.   As the host of The Dr. Tyna Show Podcast, a top ranking podcast in the health and wellness space, and an international speaker, she is dedicated to empowering others to take control of their wellbeing, heal their metabolic health, and build strength and resilience. Her cornerstone recommendations for every patient and listener: weight lifting and sunshine. Additionally, she extends her expertise to support fellow doctors in cultivating their online practices, helping them transition away from the insurance-centric model to reclaim time, financial stability, and freedom.   Dr. Tyna lives in Oregon with her husband and daughter, and is a proud dog mama. Keywords: GLP-1 agonists, semaglutide, tirzepatide, peptides, regenerative medicine, metabolic health, weight loss strategies, microdosing, hormone replacement therapy, insulin resistance, appetite suppression, personalized dosing, compounding pharmacies, side effects, gut health, SIBO (small intestinal bacterial overgrowth), slow motility, inflammation, functional medicine, neuroregeneration, autoimmune conditions, BPC-157, muscle mass, pharmaceutical dosing, diabetes management, cardiovascular health, leaky gut, obesity, perimenopause, patient empowerment, cycling peptides   Disclaimer: The views expressed in the RWS Clinician's Corner series are those of the individual speakers and interviewees, and do not necessarily reflect the views of Restorative Wellness Solutions, LLC. Restorative Wellness Solutions, LLC does not specifically endorse or approve of any of the information or opinions expressed in the RWS Clinician's Corner series. The information and opinions expressed in the RWS Clinician's Corner series are for educational purposes only and should not be construed as medical advice. If you have any medical concerns, please consult with a qualified healthcare professional. Restorative Wellness Solutions, LLC is not liable for any damages or injuries that may result from the use of the information or opinions expressed in the RWS Clinician's Corner series. By viewing or listening to this information, you agree to hold Restorative Wellness Solutions, LLC harmless from any and all claims, demands, and causes of action arising out of or in connection with your participation. Thank you for your understanding.  

Those injection-free sublingual GLP-1 drops for individualized microdosing—do they actually work? Options for treating stubborn neuropathy; Her new doctor said, “Vitamins are hogwash”—so she fired him; There is hope for tinnitus—via diet and lifestyle; I'm taking German classes, and a new study suggests it'll help me ward off cognitive decline. 

The most honest & vulnerable this pod has potentially gotten. Death, pain, drugs, cheating in relationships, divorce, mental health adversity, injury leading to inability, & disease, all experienced by one person, alone. That's what many of us men go through and I'm glad Steve opened up about it today.The Bodybuilding-friendly HRT Clinic - Get professional medical guidance on peptides AND optimizing your health as a man or bodybuilder: [ Pharma Test, IGF1, Tesamorelin, Glutathione, BPC, Semaglutide, Var troche, etc]http://www.transcendcompany.com/nylenaygaRP Hypertrophy Training App: rpstrength.com/nylePlease share this episode if you liked it. To support the podcast, the best cost-free way is to subscribe and please rate the podcast 5* wherever you find your podcasts. Thanks for watching.To be part of any Q&A, follow trensparentpodcast or nylenayga on instagram and watch for Q&A prompts on the story  https://www.instagram.com/trensparentpodcast/Huge Supplements (Protein, Pre, Defend Cycle Support, Utilize GDA, Vital, Astragalus, Citrus Bergamot): https://www.hugesupplements.com/discount/NYLESupport code 'NYLE' 10% off - proceeds go towards upgrading content productionYoungLA Clothes: https://www.youngla.com/discount/nyleCode ‘NYLE' to support the podcastLet's chat about the Podcast:Instagram: https://www.instagram.com/trensparentpodcast/TikTok: https://www.tiktok.com/@transparentpodcastPersonalized Bodybuilding Program:  https://www.nylenaygafitness.comTimestamps:0:00 Intro & Starting Convo5:19 First Meeting & Bodybuilding Beginnings10:44 Lessons from Adversity15:01 Coaching Nightmare & Recovery17:41 Naivety in Coaching → Self-Education22:49 Relationship Red Flags & Cheating Signs26:10 Porn Addiction & Marriage Impact29:41 Final Confrontation & Fresh Start32:28 Coaching Philosophy & Client Focus36:18 Toxic Relationship Cycles40:54 Gaming Escape & Life Balance42:44 Bouncing Back Strong44:21 Childhood Loss & Emotional Suppression48:24 Healing Through Community51:21 Positive Mindset Shifts54:32 Losing Loved Ones & Grief1:02:10 California Escape & Life Reorientation1:06:34 Pat's Lasting Impact1:11:37 Chosen Bonds & True Friendship1:15:19 Creating Impactful Content1:19:54 Keeping It Real on Social Media1:23:15 PED Experiments & First Prep Dosages1:27:00 Mental Strength & Stoicism1:30:05 PED Effects & Genetic Factors1:44:07 Dexa Scan & Injury Struggles1:48:19 Prep Lessons & Stress Relief1:55:10 Microdosing & Health Phases1:58:13 Travel Nightmares & Food Poisoning2:03:20 Blood Work & Health Optimization2:05:14 Rural Grind & Work Ethic2:08:37 Training Revolution & Physique Evolution2:19:59 Weight Struggles & Bulking Mindset2:23:04 Client Coach Relationships2:29:14 Moderate Dosing & Low Dose Gains2:34:14 Conscious Choices & Coaching Insights2:36:54 Prep Relationship Struggles2:41:06 Relationship Support & Competitive Balance2:43:44 Nutrition Hacks & Insulin Gains2:47:20 Gut Health & Recovery2:53:42 Stretching & Injury Prevention2:56:22 Pro Goals & Offseason Strategy2:58:54 Risk Management & Blood Work3:00:48 Final Message & Positive Impact

Quick summaries of articles 51-60. Enjoy! 51. Fun Activities and Recovery Acuff, S. F., et al. A brief measure of non-drug reinforcement: Association with treatment outcomes during initial substance use recovery. Drug and Alcohol Dependence, 256, 111092. 52. Buprenorphine-precipitated Fentanyl Withdrawal Thakrar AP, et al. Buprenorphine-Precipitated Withdrawal Among Hospitalized Patients Using Fentanyl. JAMA Netw Open. 2024 Sep 3;7(9):e2435895. 53. Methadone Vs. Buprenorphine Nosyk B, Et al. Buprenorphine/Naloxone vs Methadone for the Treatment of Opioid Use Disorder. JAMA. 2024 Oct 17. 54. High Daily Doses of Buprenorphine Axeen S, et al. Association of Daily Doses of Buprenorphine With Urgent Health Care Utilization. JAMA Netw Open. 2024 Sep 3;7(9):e2435478. 55. How Buprenorphine Works in Pregnancy Caritis, Steve N. MD; et al. A Pharmacologic Evaluation of Buprenorphine in Pregnancy and the Postpartum Period. Journal of Addiction Medicine ():10.1097/ADM.0000000000001380, September 2, 2024. 56. How Many Quite Attempts Does It Take? Fontes RM, et al. Beyond the first try: How many quit attempts are necessary to achieve substance use cessation? Drug Alcohol Depend. 2024 Dec 8;267:112525. 57. What is Recovery? Zemore SE, et al. Understanding the Shared Meaning of Recovery From Substance Use Disorders: New Findings From the What is Recovery? Study. Subst Abuse. 2023 Sep 15;17:11782218231199372. 58. Semaglutide for Alcohol Use Disorder (The RCT) Hendershot CS, et al. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2025 Feb 12:e244789. 59. Low-Dose Buprenorphine Initiation (Micro-induction) Suen LW, et al. Outpatient Low-Dose Initiation of Buprenorphine for People Using Fentanyl. JAMA Netw Open. 2025 Jan 2;8(1):e2456253. 60. Lisdexamfetamine for methamphetamine use disorder Ezard N, et al LiMA Investigator Group. Lisdexamfetamine in the treatment of methamphetamine dependence: A randomised, placebo-controlled trial. Addiction. 2024 Dec 19. --- This podcast offers category 1 and MATE-ACT CME credits through MI CARES and Michigan State University. To get credit for this episode and others, go to this link to make your account, take a brief quiz, and claim your credit. To learn more about opportunities in addiction medicine, visit MI CARES. CME: https://micaresed.org/courses/podcast-addiction-medicine-journal-club/ --- Original theme music: composed and performed by Benjamin Kennedy Audio editing: Michael Bonanno Executive producer: Dr. Patrick Beeman A podcast from Ars Longa Media --- This is Addiction Medicine Journal Club with Dr. Sonya Del Tredici and Dr. John Keenan. We practice addiction medicine and primary care, and we believe that addiction is a disease that can be treated. This podcast reviews current articles to help you stay up to date with research that you can use in your addiction medicine practice. The best part of any journal club is the conversation. Send us your comments on social media or join our Facebook group. --- Email: addictionmedicinejournalclub@gmail.com Facebook: @AddictionMedJC Facebook Group: Addiction Medicine Journal Club Instagram: @AddictionMedJC Threads: @AddictionMedJC YouTube: addictionmedicinejournalclub Twitter/X: @AddictionMedJC --- Addiction Medicine Journal Club is intended for educational purposes only and should not be considered medical advice. The views expressed here are our own and do not necessarily reflect those of our employers or the authors of the articles we review. All patient information has been modified to protect their identities. Learn more about your ad choices. Visit megaphone.fm/adchoices

Even though GLP-1 drugs have helped nearly 20 million people shed weight across the world since 2021, Indians had to wait until 2025 to get in on the action legally.To be fair, the country wasn't entirely in the dark. Semaglutide—the molecule behind pharma giant Novo Nordisk's blockbuster drugs Ozempic and Wegovy—was already available for diabetes treatment. But this March, Eli Lilly's Mounjaro (which uses a different molecule, tirzepatide) entered the market. In July, Wegovy arrived. And suddenly, India went from “we know GLP-1” to “we want the skinny shot”.Since then, the GLP-1 market in India—across diabetes and weight loss—has grown from Rs 531 crore to Rs 628 crore. And now, depending on the vantage point, things are about to get much bigger. And much cheaper.And naturally, pretty much every major Pharma major wants in on the action. Tune in. Do you work in IT? Take our surveyWant to join The Ken's team? Fill this form. 

TakeawaysThe podcast features Dr. Grant Tinsley, a body composition expert.The discussion revolves around a case series on body composition effects.GLP-1 receptor agonists are a focus of the research.The importance of resistance training in weight loss is emphasized.Patient case studies provide insights into individual experiences.The first patient lost a significant amount of fat mass while preserving lean mass.The second patient achieved remarkable body composition changes in a short time.The third patient showed positive changes over a longer duration.The need for more randomized trials is highlighted.The conversation underscores the role of exercise and nutrition in weight management.Tap or Click here to see more from Dr. GrantTap here for scientific references in this episode.

Send us a textWelcome back Rounds Table Listeners! We are back today with a Classic Rapid Fire episode. This week, Drs. Mike and John Fralick discuss two recent papers: the effects of infrequent zoledronate administration on vertebral fracture prevention in early postmenopausal women, and the efficacy and safety of semaglutide in adults with type 1 diabetes and obesity. Two papers, here we go!Fracture Prevention with Infrequent Zoledronate in Women 50 to 60 Years of Age (0:00 – 10:24)Semaglutide in Adults with Type 1 Diabetes and Obesity (10:25 – 17:48)And for the Good Stuff (17:49 – 19:46):Canadian tennis player Victoria Mboko wins the Canadian Open!The I'm Pharmacy podcast— coming soon to www.medicinepods.com.Thank you to our sponsor, FIGS scrubs. Rounds Table listeners can save 20% on their next purchase with code FIGSCA at https://www.wearfigs.com/.Questions? Comments? Feedback? We'd love to hear from you! @roundstable @InternAtWork @MedicinePods

In this episode, we look at the new "wonder drugs" that are wreaking havoc on people's lives.Show NotesAlcor Life Extension Foundation: https://en.wikipedia.org/wiki/Alcor_Life_Extension_FoundationFred and Linda Chamberlain https://en.wikipedia.org/wiki/Fred_and_Linda_Chamberlain Mike Darwin https://en.wikipedia.org/wiki/Mike_DarwinThe Great Ozempic Scam https://www.theburningplatform.com/2024/09/12/the-great-ozempic-scam Semaglutide https://en.wikipedia.org/wiki/Semaglutide Drug trial snapshot:  https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trial-snapshot-ozempic Can Ozempic Kill You? https://www.motleyrice.com/diabetes-lawsuits/ozempic/safe-for-weight-loss/deathsTirzepatide, or Mounjaro https://en.wikipedia.org/wiki/Tirzepatide Tirzepatide is a peptide The Cardiovascular Effect of Tirzepatide: A Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide Dual Agonist https://pubmed.ncbi.nlm.nih.gov/37800107/ This Is What Happens When You Inject Yourself With Reptile Venom Peptides Marketed as FDA-Approved Weight Loss Drugs https://discernreport.com/this-is-what-happens-when-you-inject-yourself-with-reptile-venom-peptides-marketed-as-fda-approved-weight-loss-drugs/

Ozempic, Wegovy, & Other Semaglutide medications are some of the hottest medications on the market today. Join our GLP-1 expert, Rachel Derylo, who will explain the effects of GLP-1s on the body and set the narrative on the proper use of these medications. We will discuss strategies to mitigate being under-muscled which is a common and chronic health issue. Together we will step into autonomy over your health with the tool of GLP-1s.

Dr. Sarah Marino doesn't just treat symptoms; she treats people. She transitioned from hospital medicine into direct primary care (DPC) so she could offer something too many patients go without: time, access, and transparency.Her model guarantees next-day availability for urgent needs, HIPAA-compliant direct texting, and longer visits—an hour for the first, then 30 minutes each time after. It's membership-based care that feels personal, with a clear menu of services, no surprise lab bills, and prices lower than insurance. For her, it's about putting the power back in patients' hands.The healthcare system is frustrating, inflated, and lacking in transparency, so she built something better. Her care is grounded in four pillars: nutrition, mental health, sleep, and movement. Medications come later, after she's taken the time to really understand what's going on.Based in Dripping Springs, her mission is simple: to support longevity and well-being without turning into a prescription machine.To learn more about Dr. Sarah Marino's Dripping Springs Direct Primary CareFollow Dr. Marino on Instagram @marinomedicaABOUT MEET THE DOCTOR The purpose of the Meet the Doctor podcast is simple.  We want you to get to know your doctor before meeting them in person because you're making a life changing decision and time is scarce. The more you can learn about who your doctor is before you meet them, the better that first meeting will be. When you head into an important appointment more informed and better educated, you are able to have a richer, more specific conversation about the procedures and treatments you're interested in. There's no substitute for an in-person appointment, but we hope this comes close.Meet The Doctor is a production of The Axis. Made with love in Austin, Texas.Are you a doctor or do you know a doctor who'd like to be on the Meet the Doctor podcast?  Book a free 30 minute recording session at meetthedoctorpodcast.com.Host: Eva Sheie Assistant Producers: Mary Ellen Clarkson & Hannah BurkhartEngineering: Daniel Croeser and Spencer ClarksonTheme music: A Grace Sufficient by JOYSPRING

Dr. Centor discusses outcomes in patients with type 2 diabetes when treated with semaglutide or dulaglutide versus empagliflozin with Drs. Kevin Kip and Anum Saeed.

The most uncensored guest I've ever had. He always has knowledge to share that has me realize there's something new for me I haven't been looking into.The Bodybuilding-friendly HRT Clinic - Get professional medical guidance on peptides AND optimizing your health as a man or bodybuilder: [ Pharma Test, IGF1, Tesamorelin, Glutathione, BPC, Semaglutide, Var troche, etc]https://transcendcompany.com/patient-intake-form/?ls=Nyle+NaygaRP Hypertrophy Training App: rpstrength.com/nylePlease share this episode if you liked it. To support the podcast, the best cost-free way is to subscribe and please rate the podcast 5* wherever you find your podcasts. Thanks for watching.To be part of any Q&A, follow trensparentpodcast or nylenayga on instagram and watch for Q&A prompts on the story  https://www.instagram.com/trensparentpodcast/Huge Supplements (Protein, Pre, Defend Cycle Support, Utilize GDA, Vital, Astragalus, Citrus Bergamot): https://www.hugesupplements.com/discount/NYLESupport code 'NYLE' 10% off - proceeds go towards upgrading content productionYoungLA Clothes: https://www.youngla.com/discount/nyleCode ‘NYLE' to support the podcastLet's chat about the Podcast:Instagram: https://www.instagram.com/trensparentpodcast/TikTok: https://www.tiktok.com/@transparentpodcastPersonalized Bodybuilding Program:  https://www.nylenaygafitness.comTimestamps:00:00:00 – Intro00:03:19 – Caffeine Kickstart00:06:19 – Metabolism & Side Effects Breakdown00:10:55 – Stack Design & Mixing Compounds00:14:48 – Injection Methods & GH Dosing00:20:15 – Practicality in HRT & Nuanced Advice00:25:05 – Injection Scar Tissue & Absorption00:26:56 – Prep Strategy & Mini Cuts00:32:17 – Coaching Approaches & Hormone Levels00:35:14 – Estrogen, Gyno & Anabolics00:41:45 – Healthcare System Critique00:45:40 – Medical Ethics & Corruption00:50:56 – Progress Algorithms & Training Style00:55:45 – Aging, Growth & Rep Ranges01:00:42 – EQ vs Primo & Kidney Concerns01:03:27 – Anecdotal Evidence01:18:43 - Methylene Blue Cancer Risk01:21:11 – Retatrutide & Prep Secrets01:27:08 – Masteron vs Primo & Cycle Choices01:31:54 – Back Growth & Training Pitfalls01:35:35 – Genetic Risks & Bodybuilding Myths01:38:38 – High-Frequency Gains01:40:27 – Final Message & Wrap-Up

Liver, Lipids, and the Left Ventricle

Dr. Robert Baron explores current strategies for treating obesity, emphasizing evidence-based approaches to diagnosis, lifestyle change, medication, and long-term weight maintenance. He explains the limitations of body mass index (BMI) as a diagnostic tool and highlights the importance of assessing both excess fat and its health consequences. He reviews dietary principles, including calorie reduction, avoiding added sugars, and the importance of sustainable habits over specific diet types. He also discusses the role of physical activity—particularly strength training—for preserving muscle and improving long-term outcomes. Baron evaluates weight loss medications such as semaglutide and tirzepatide, noting their benefits, side effects, and the need for continued use to maintain weight loss. [Health and Medicine] [Show ID: 40757]

Dr. Robert Baron explores current strategies for treating obesity, emphasizing evidence-based approaches to diagnosis, lifestyle change, medication, and long-term weight maintenance. He explains the limitations of body mass index (BMI) as a diagnostic tool and highlights the importance of assessing both excess fat and its health consequences. He reviews dietary principles, including calorie reduction, avoiding added sugars, and the importance of sustainable habits over specific diet types. He also discusses the role of physical activity—particularly strength training—for preserving muscle and improving long-term outcomes. Baron evaluates weight loss medications such as semaglutide and tirzepatide, noting their benefits, side effects, and the need for continued use to maintain weight loss. [Health and Medicine] [Show ID: 40757]

Dr. Robert Baron explores current strategies for treating obesity, emphasizing evidence-based approaches to diagnosis, lifestyle change, medication, and long-term weight maintenance. He explains the limitations of body mass index (BMI) as a diagnostic tool and highlights the importance of assessing both excess fat and its health consequences. He reviews dietary principles, including calorie reduction, avoiding added sugars, and the importance of sustainable habits over specific diet types. He also discusses the role of physical activity—particularly strength training—for preserving muscle and improving long-term outcomes. Baron evaluates weight loss medications such as semaglutide and tirzepatide, noting their benefits, side effects, and the need for continued use to maintain weight loss. [Health and Medicine] [Show ID: 40757]

Thank you for listening to The Peptide Podcast. If you enjoyed the show and want to support what we do, head over to our Partners Page. You'll find some amazing brands we trust—and by checking them out, you're helping us keep the podcast going.  Today, we're diving into one of the most talked-about topics in health and weight loss right now: GLP-1 medications like semaglutide and the newer dual GIP/GLP-1s like tirzepatide. You've probably seen the headlines, scrolled past a few TikToks, or heard a friend mention it — but with all that noise comes a lot of confusion, half-truths, and flat-out myths. Today we're breaking it all down. What's real? What's hype? And what do you actually need to know if you're using these medications — or thinking about it? Let's separate science from scare tactics and get to the truth, one myth at a time. Myth #1: GLP-1s Cause Dangerous Muscle Loss The claim:  “GLP-1s cause massive muscle loss.” Truth: This is an overstatement. Some loss of lean mass is normal with any kind of weight loss — whether it's through diet, medication, or surgery. What studies show is that with medications like semaglutide (Wegovy) and tirzepatide (Zepbound), about 20–25% of the total weight lost comes from lean mass, and the rest is fat — which is exactly what we're targeting in obesity treatment. That 20–25% figure isn't unique to these meds; it's actually pretty typical in weight loss without focused resistance training or optimized protein intake. You may also hear “You'll lose all your muscle and become frail on GLP-1s.” Truth: You won't “lose all your muscle.” In fact, muscle loss is preventable by maintaining adequate protein intake, resistance training, and managing weight loss pace. Furthermore, many patients gain strength and mobility as excess weight comes off. And lastly, my favorite myth is “You can't preserve muscle on GLP-1s.” Truth: That's completely false — muscle loss isn't inevitable on GLP-1s if you take the right approach. You can absolutely preserve muscle by making a few intentional choices: aim for enough protein each day (a good goal is around 0.8 grams per pound of body weight), include some strength or resistance training a couple times a week, and avoid losing weight too quickly. These simple steps go a long way in protecting your lean mass while still getting all the benefits of weight loss. One study on semaglutide showed that people lost an average of about 15% of their body weight, and only around 3–4% of that was lean mass. So if someone drops 30 pounds, maybe 6 to 8 of those pounds might be lean mass—not ideal, but definitely not disastrous either, and very manageable with the right lifestyle habits.  The truth is, while some lean mass loss is expected with any type of weight loss, research shows that most of the weight lost on GLP-1s is actually fat, not muscle. For example, in the STEP 1 trial, about 80% of the weight lost on semaglutide came from fat, and only about 20% from lean tissue (as we mentioned earlier).  The SURMOUNT-1 trial with tirzepatide showed similar results—significant fat loss with relatively preserved muscle, especially when paired with resistance training. And that's important, because preserving muscle during weight loss helps protect metabolism, strength, and overall health. With good nutrition and movement, GLP-1s can lead to healthier body composition—not just a lower number on the scale. Okay, moving along to the next myth … Myth #2: GLP-1s Can Cause Blindness The truth: This myth stems from concerns about diabetic retinopathy worsening, which is tied to how quickly blood sugar drops, not to the drug itself. In the SUSTAIN-6 trial (Marso et al., NEJM, 2016), a small subset of patients with pre-existing advanced diabetic retinopathy saw transient worsening—but only in those with rapid improvements in A1c. No increased rates of blindness or new-onset retinopathy have been found in non-diabetic patients using GLP-1s for weight loss. The bottom line is that those without advanced diabetic eye disease, there's no increased risk of blindness. Patients with diabetic retinopathy should be monitored closely—but this is about glycemic management, not a direct effect of the medication. Myth #3: GLP-1s Cause Kidney or Liver Damage The truth: This is false. In fact, GLP-1 agonists may protect kidney and liver function—especially in patients with diabetes or fatty liver disease. The most recent notable study showing kidney‑protective effects of a GLP‑1 receptor agonist is the FLOW trial, which evaluated semaglutide in people with type 2 diabetes and chronic kidney disease (CKD). This double‑blind, randomized, placebo‑controlled trial included 3,533 participants followed for a median of 3.4 years and found that semaglutide reduced the risk of major kidney‑related events—including kidney failure, substantial eGFR decline, and death from renal or cardiovascular causes—by 24% compared to placebo. A 2025 meta-analysis of multiple randomized controlled trials (11 studies, 85,373 participants) concluded that GLP‑1 receptor agonists reduced the risk of composite kidney failure outcomes by 18%, kidney failure by 16%, and all‑cause death by 12%. And let's not forget the SMART trial, involving obese patients with kidney disease but without diabetes, found that semaglutide protected kidney function in this non‑diabetic, CKD‑affected population.  When it comes to the liver, there's actually growing evidence they're actually helping reverse non-alcoholic fatty liver disease (NAFLD). The STEP 1 MRI substudy and SURPASS-3 MRI substudy have shown people on these medications can reduce liver fat by 30 to even 50% and in some cases, completely resolve liver inflammation — that more serious form called NASH, where fat is combined with inflammation and early scarring. The LEAN trial found that nearly 60% of people taking semaglutide had resolution of NASH, without worsening their liver scarring. That's huge. And even better, we're seeing these effects even in people who don't have diabetes. Just losing weight helps fatty liver, but these meds seem to do more than that — they actually target inflammation and fat storage in the liver itself.. The bottom line is GLP-1s are not nephrotoxic or hepatotoxic. In fact, they may be organ-protective—especially for people with underlying metabolic issues. Myth #4: These Drugs Lead to Bone Loss The claim: “You'll get osteoporosis from losing too much weight!” The truth: While extreme weight loss can affect bone density, GLP-1s themselves do not cause bone loss, and may even have neutral or protective effects on bone. A 2022 study in Bone found no significant change in BMD (bone mineral density) in adults treated with semaglutide for obesity. While the SUSTAIN and PIONEER programs found no increased risk of fractures in semaglutide-treated patients versus placebo. Truly, concerns about bone loss are more relevant in extreme calorie restriction or eating disorders—not evidence-based GLP-1 treatment with appropriate nutrition. Myth #5: Everyone Gets Gastroparesis The claim: “These medications paralyze your stomach” The truth: GLP-1s slow gastric emptying, which is part of how they work—making you feel full longer. But this is dose-dependent and typically reversible. A 2023 FDA safety review found that true gastroparesis is extremely rare and resolves when the drug is stopped. Reality check: Nausea, early satiety, and mild bloating are common but manageable side effects. True, lasting gastroparesis is not typical, especially when doses are titrated gradually. Myth #6: GLP-1s Make Your Hair Fall Out The claim: “You'll lose a ton of hair—just like with crash diets” The truth: Hair shedding is not directly caused by GLP-1 medications. Instead, it's often a temporary, non-scarring condition called telogen effluvium, which can happen with any rapid weight loss, regardless of the method. A 2023 analysis from the American Academy of Dermatology emphasized that telogen effluvium is common with surgical or medical weight loss, especially if patients lose more than 10% of their body weight within a few months. In clinical trials like STEP and SURMOUNT, hair loss was not listed as a common side effect, but patient-reported data show it occurs occasionally—likely tied to nutritional stress, not the drug itself. So why does hair loss happen? We've talked about this before, but I don't want to leave this important information out.  Hair follicles are sensitive to internal stress. Rapid changes in caloric intake, nutrient levels (like iron, zinc, and biotin), or hormone balance can push hairs into the shedding phase. This is a delayed effect, often showing up 2–3 months after weight loss begins, and it typically resolves within 6–12 months. What helps is slower, sustained weight loss, prioritizing protein intake, supplementing iron, zinc, and biotin if deficient, and avoiding very low-calorie diets and over-restriction. Myth #6: GLP-1s Cause Dehydration It's a common myth that GLP-1 medications cause dehydration — but that's not exactly true. The medication itself doesn't directly dehydrate you. What can happen is that some people experience nausea, vomiting, or a reduced appetite early on, which can lead to drinking less water without realizing it. That's where the dehydration risk comes in. A good general rule for staying hydrated is to aim for half your body weight in ounces of water per day. So, for example, if you weigh 160 pounds, try to drink around 80 ounces daily — more if you're active or live in a hot climate. Electrolytes can also be really helpful, especially if you're feeling tired, dizzy, or crampy. I like LMNT packets — they're a clean option with no sugar and a good balance of sodium, magnesium, and potassium. The sodium in LMNT packets helps keep you hydrated by pulling water into your cells and helping your body retain the fluids it needs to function properly. Just one a day can make a big difference in how you feel. Myth #7: You Have to Stay on GLP-1s Forever or You'll Gain All the Weight Back The claim: “As soon as you stop taking it, all the weight comes back” The truth: Yes—some weight regain is likely after stopping GLP-1 medications. But that doesn't mean they're ineffective or that you're doomed to rebound completely. The same pattern happens after any type of weight loss intervention, whether it's a diet, surgery, or medication. The STEP 4 trial (Wilding et al., 2022) showed that participants who stopped semaglutide after 20 weeks regained an average of 6% of their weight loss over the next year. But it's important to note that they still weighed less than at baseline—and many continued to experience improvements in blood pressure, cholesterol, and insulin sensitivity. Similarly, in SURMOUNT-4, patients who stopped tirzepatide also regained weight, but less than they lost. So why does this weight gain happen? I feel like the answer to this is obvious, but I've found that it's not.  GLP-1s change your appetite and hunger cues. Once the medication is stopped, your body's baseline hunger signals return—and often with increased intensity, due to metabolic adaptation. But this isn't unique to GLP-1s. The same thing happens after crash diets, keto, intermittent fasting, or bariatric surgery if long-term changes aren't made. The real issue isn't the drug—it's the lack of a plan after the drug. To help make results sustainable, we need to use the medication as a tool, not a crutch. We should use it to help us lose weight and understand our hunger cues, while transitioning to a whole foods, protein based diet coupled with resistance training to help preserve and build muscle.  Just remember, if you're coming off a GLP-1 and want to keep the momentum going, the key is to approach it thoughtfully. Tapering slowly under medical supervision can help your body adjust and reduce the chances of weight regain. At the same time, this is a great moment to double down on the habits that helped you feel your best while on the medication. Think ongoing support—like working with a health coach, joining a support group, or even doing behavioral therapy—to help reinforce those long-term lifestyle changes. It's not just about what you stop; it's about what you keep doing that matters most. You don't necessarily have to stay on GLP-1s forever—but if you stop without a plan, some weight regain is very likely. Think of them like glasses: they help you see clearly while you build the habits to eventually navigate without them. For some, that may mean staying on a lower maintenance dose long-term—just like with blood pressure or cholesterol meds. What are my final thoughts? I want to be clear—GLP-1s aren't magic. But they are powerful tools when paired with education, support, and smart lifestyle changes.  Myths like ‘you'll go blind,' ‘you'll lose all your hair,' or ‘you'll be stuck on these meds forever' aren't just misleading and downright false—they discourage people from getting real help.  So if you're thinking about these medications, get informed, ask the hard questions, and make your decision based on science—not fear. Thank you for listening to The Peptide Podcast. If you enjoyed the show and want to support what we do, head over to our Partners Page. You'll find some amazing brands we trust—and by checking them out, you're helping us keep the podcast going.  Until next time, be well, and as always, have a happy, healthy week.

In this episode, Mike discusses the latest GLP-1 craze, which has to do with healthy weight individuals using these medications. ------------------------------------------------Click here to apply for coaching!For some amazing resources and to be a part of a badass community, join our FB group HEREThe personality assessment is now available online! Click here to take the assessment and find out what your personality tells us about the way you should be training and eating.Take the assessment here!To learn more about Neurotyping, visit www.neurotypetraining.comFollow Mike on IG at @coach_mike_millner

The Bodybuilding-friendly HRT Clinic - Get professional medical guidance on peptides AND optimizing your health as a man or bodybuilder: [ Pharma Test, IGF1, Tesamorelin, Glutathione, BPC, Semaglutide, Var troche, etc]https://transcendcompany.com/patient-intake-form/?ls=Nyle+NaygaRP Hypertrophy Training App: rpstrength.com/nylePlease share this episode if you liked it. To support the podcast, the best cost-free way is to subscribe and please rate the podcast 5* wherever you find your podcasts. Thanks for watching.To be part of any Q&A, follow trensparentpodcast or nylenayga on instagram and watch for Q&A prompts on the story  https://www.instagram.com/trensparentpodcast/Huge Supplements (Protein, Pre, Defend Cycle Support, Utilize GDA, Vital, Astragalus, Citrus Bergamot): https://www.hugesupplements.com/discount/NYLESupport code 'NYLE' 10% off - proceeds go towards upgrading content productionYoungLA Clothes: https://www.youngla.com/discount/nyleCode ‘NYLE' to support the podcastLet's chat about the Podcast:Instagram: https://www.instagram.com/trensparentpodcast/TikTok: https://www.tiktok.com/@transparentpodcastPersonalized Bodybuilding Program:  https://www.nylenaygafitness.com0:00 – Intro1:55- Prep vs Off-Season Diet4:56 – Stretching before the show6:55 - Dubai Pro Success9:40 – Switching to Machines12:07 – Dealing with Personal Issues15:45 – Coaching Myself17:52 – Stomach Issues & Solutions23:52 – Cutting Compounds Early27:25 – Working with Patrick29:38 – Trusting My Instincts34:00 – Improving Lats41:02 – Leg Training Insights44:39 – Reverse Grip for Lats45:35 – Using Drop Sets & Intensifiers53:34 – GLP-1 & Digestion Concerns1:08:30 – Secrets to Insane Conditioning1:13:20 – Making Weight for Shows1:21:00 – Moderate Peak Week Philosophy1:23:30 – Gradual Carb Increase Strategy1:38:43 – Michaels's Favourite Off-Season1:40:35 – High Doses, No Gains1:49:30 - Compounds that didn't work for Michael1:54:50 – Financing Bodybuilding as a Pro1:59:38 - Mindset is everything2:04:50  - Most important supplements2:07:00 – Final Message to the World

Pharma firms are pouncing on opportunity as patents on world's second-bestselling drug, which goes by brand names Ozempic and Wegovy, are expiring in nearly 100 nations.  

VISIT OUR LINKS: https://linktr.ee/manonthemounjaro

In response to the article I wrote in The Times about whether I was daft for not using skinny jabs to lose weight, I thought revisiting my conversation with Johann Hari about his book Magic Pill, which extensively researched the benefits, limitations and risks of GLP-1 Agonist drugs such as Ozempic, Semaglutide, Wegovy and Mounjaro.Johann is thorough and meticulous in his research and this interview, originally broadcast in 2024, was before weight loss drugs became as mainstream and as widely prescribed as they are today.One of the experts Johann interviewed during his years of research, stated that the cultural impact of GLP-1s was as significant as the smart phone. At the time, it seemed like a very bold statement, but in the year since we spoke, I think it's hard to argue that they haven't completely changed the way we talk about weight, weight loss, diets, food and more...I'd love to hear your thoughts on this episode. Email me at office@emmaguns.com or Subscribe to my Substack and join the chat there. Hosted on Acast. See acast.com/privacy for more information.

In first-ever study, keto diet scores vs. Parkinson's; Walk away from dementia; Loneliness can kill, but negative social ties can hasten biological aging; Researchers isolate potent memory compound from sage, rosemary; Sketchy knockoff weight loss drugs are flooding the marketplace; The popular vitamin you shouldn't take for sarcoidosis; When osteoporosis is so severe that even minor trauma causes rib fractures.

IFBB Pro Open Bodybuilder, 2023 Chicago Pro Champ, & Olympian, known for his wild proportions & training style.The Bodybuilding-friendly HRT Clinic - Get professional medical guidance on peptides AND optimizing your health as a man or bodybuilder: [ Pharma Test, IGF1, Tesamorelin, Glutathione, BPC, Semaglutide, Var troche, etc]https://transcendcompany.com/patient-intake-form/?ls=Nyle+NaygaRP Hypertrophy Training App: rpstrength.com/nylePlease share this episode if you liked it. To support the podcast, the best cost-free way is to subscribe and please rate the podcast 5* wherever you find your podcasts. Thanks for watching.To be part of any Q&A, follow trensparentpodcast or nylenayga on instagram and watch for Q&A prompts on the story  https://www.instagram.com/trensparentpodcast/Huge Supplements (Protein, Pre, Defend Cycle Support, Utilize GDA, Vital, Astragalus, Citrus Bergamot): https://www.hugesupplements.com/discount/NYLESupport code 'NYLE' 10% off - proceeds go towards upgrading content productionYoungLA Clothes: https://www.youngla.com/discount/nyleCode ‘NYLE' to support the podcastLet's chat about the Podcast:Instagram: https://www.instagram.com/trensparentpodcast/TikTok: https://www.tiktok.com/@transparentpodcastPersonalized Bodybuilding Program:  https://www.nylenaygafitness.comTimestamps:00:00 - Intro02:05 - Pod Setup03:41 - Relationships & Personal Stories05:04 - Dealing with Loss13:20 - Grief and Maintaining Routine16:27 - Navigating Life Transitions21:40 - Contest Prep Updates27:08 - Gut Health Protocol Impact30:59 - Lifelong Gut Issues42:36 - Justin being comparatively small44:35 - Cycles, Training Styles & Genetics50:16 - You are not gonna feel great all the time!54:44 - Eric Janicki & Training to Failure01:03:44 - Journey to Bodybuilding01:08:52 - Longevity in Bodybuilding01:14:25 - Growth Hormone Experiences01:18:34 - Training Style Evolution01:20:09 - Coach Behind Justine & Motivation01:27:03 - Balancing Bodybuilding, Business and Relationships01:32:02 - Being Raised Perfectly01:40:33 - Moderate Dosage Benefits & Being Health Conscious01:47:49 - Consistency in Training01:55:21 - Acne Struggles & Solutions02:04:58 - Obsession vs. Balance in Prep02:09:06 - Peak Week Nutrition02:14:04 - Frenchie vs. Pug Debate02:19:33 - Cannabis Business Role02:24:33 - Delegating in Business02:27:00 - Getting competition lean on burgers02:32:23 - Training Frequency Benefits02:39:55 - Exercise-Specific Training02:43:59 - Back Density Movements02:46:34 - Olympia Stress Disaster02:57:10 - Do What You Love

Strongest legal performance enhancers, methods, and more to improve your recovery, endurance, overthinking, mental clarity, cognition, fatigue threshold, longevity, and so much more to get the edge on your competition.The Bodybuilding-friendly HRT Clinic - Get professional medical guidance on peptides AND optimizing your health as a man or bodybuilder: [ Pharma Test, IGF1, Tesamorelin, Glutathione, BPC, Semaglutide, Var troche, etc]https://transcendcompany.com/patient-intake-form/?ls=Nyle+NaygaRP Hypertrophy Training App: rpstrength.com/nylePlease share this episode if you liked it. To support the podcast, the best cost-free way is to subscribe and please rate the podcast 5* wherever you find your podcasts. Thanks for watching.To be part of any Q&A, follow trensparentpodcast or nylenayga on instagram and watch for Q&A prompts on the story  https://www.instagram.com/trensparentpodcast/Huge Supplements (Protein, Pre, Defend Cycle Support, Utilize GDA, Vital, Astragalus, Citrus Bergamot): https://www.hugesupplements.com/discount/NYLESupport code 'NYLE' 10% off - proceeds go towards upgrading content productionYoungLA Clothes: https://www.youngla.com/discount/nyleCode ‘NYLE' to support the podcastLet's chat about the Podcast:Instagram: https://www.instagram.com/trensparentpodcast/TikTok: https://www.tiktok.com/@transparentpodcastPersonalized Bodybuilding Program:  https://www.nylenaygafitness.com00:00:00 – Intro to Dr. Scott Sherr00:02:27 – Podcast Warm Up - Dr. Scott's teachings and bodybuilding00:05:40 – Brain Health in Bodybuilding00:08:12 – Overtraining & Parasympathetic Recovery Challenges00:10:32 – Post-Workout Parasympathetic Strategies - GABA00:14:02 – CO2 Tolerance Training for Performance00:16:42 – Breathwork Techniques for CO2 Training00:20:03 – Caffeine & Nicotine in Workouts00:23:12 – Individual Responses to Supplements00:27:13 – Deep Dive into GABA & Supplementation Risks00:37:40 – GHB & Phenibut for Deep Sleep00:42:44 – GABA supplementation/ Glutamine & Gut Health00:46:15 – Caffeine & Nicotine for Brain Health00:52:56 – Nootropics: Health vs. Performance01:04:11 – Blood Sugar Control & Key Supplements01:12:49 – Methylene Blue for Performance01:20:29 – Hydration + Methylene Blue Travel Stack01:22:03 – Methylene Blue Dosing, Safety & Delivery01:28:41 – Methylene Blue Success Stories01:33:50 – Sleep Optimization: Sauna & Hyperbaric Therapy01:39:03 – Hyperbaric Therapy Explained01:50:56 – Mitochondrial Health & Sexual Performance01:53:24 – Where to Find Dr. Scott

How the STEP-UP trial came to life,  and what made the 7.2mg dose possibleWhat the data actually says about weight loss and side effects at higher dosesWhy trial design, pharmacokinetics, and estimands matter more than you thinkWhat's coming next in obesity meds: duals, triples, and even antagonistsThe real talk on intermittent fasting, access issues, and preaching vs. scienceSign up for Dr. Spencer''s Clinic

GLP-1 medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are reshaping how we treat obesity — but there's so much confusion and stigma. That's why we sat down with leading obesity specialist Dr. Spencer Nadolsky for an honest, empowering conversation.We break down how GLP-1s actually work, why food noise is real, and what people aren't being told about compounded semaglutide, weight regain after bariatric surgery, and long-term success.If you've felt frustrated, misunderstood, or stuck — this episode is for you. Whether you're post-op, on medication, or considering your options, this episode brings science, support, and real talk together.